Artelo Biosciences Inc (ARTL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.94 (-0.76%), Market cap $0.00B, 52-week low–high $0.95 ~ $28.50.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral
Financial statements, price targets, institutional (13F) holdings and related news for Artelo Biosciences Inc are updated in real time on BlackAll Trade.
Artelo Biosciences Inc trades at $3.94 (-0.76%). Real-time quotes and charts are available on BlackAll Trade.
Artelo Biosciences Inc has a market cap of about $0.00B.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidat